CSIR begins Section II scientific trials of Niclosamide for Covid remedy


Picture Supply : AP

CSIR begins Section II scientific trials of Niclosamide for Covid remedy (Representational Picture)

The CSIR and Laxai Life Sciences Personal Restricted have initiated section II scientific trials of anti-helminitic drug ‘Niclosamide’ for the remedy of COVID-19 sufferers, a press release mentioned on Sunday. The trial is a multi-centric, randomised, open label scientific examine to guage the efficacy, security and tolerability of Niclosamide for treating hospitalised COVID-19 sufferers.

Niclosamide has been extensively used prior to now for treating tapeworm an infection in adults in addition to youngsters. The protection profile of this drug has been examined over time and has been discovered secure for human consumption at completely different dose ranges, the Council for Scientific and Industrial Analysis (CSIR) mentioned.

Ram Vishwakarma, advisor to Director Basic CSIR, identified that in a display screen to determine medication that may inhibit syncytia formation, Niclosamide was recognized as a promising repurposed drug by a analysis group from King’s Faculty London, which collaborated on this undertaking.

The syncytia or fused cells noticed within the lungs of sufferers with novel coronavirus an infection in all probability consequence from the fusogenic exercise of the SARS-CoV-2 spike protein and Niclosamide can inhibit this syncytia formation.

Independently, a collaborative analysis between CSIR-Indian Institute of Integrative Drugs (IIIM), Jammu and the Nationwide Centre for Organic Sciences, Bengaluru had just lately demonstrated that Niclosamide was additionally a possible SARS-CoV2 entry inhibitor, blocking the viral entry by pH dependent endocytic pathway.

Given these two unbiased experimental research, Niclosamide has now emerged as a promising drug candidate for scientific trial in COVID-19 sufferers.

Srivari Chandrashekhar, director, CSIR-Indian Institute of Chemical Know-how (IICT) Hyderabad highlighted that the Lively Pharmaceutical Ingredient (API) is being made by Laxai Life Sciences based mostly on improved expertise developed at IICT and the lab is a companion on this essential scientific trial which may present price efficient therapeutic choices for sufferers if the continuing trial is profitable.

Ram Upadhayaya, CEO, Laxai Life Sciences famous that realising the potential of Niclosamide, efforts had been initiated final yr itself to undertake the scientific trials.


Having acquired approval from drug regulators, the scientific trial has been initiated this week at completely different websites and is anticipated to be accomplished inside Eight-12 weeks, the CSIR mentioned.

Primarily based on profitable scientific proof generated throughout the scientific trials in Indian research, emergency use authorisation could also be sought in order that extra remedy choices can be found to COVID-19 sufferers, it added.

ALSO READ: Reliance proposes use of Niclosamide drug for treating COVID-19

Newest India Information



Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *